Hifibio Therapeutics’ BTLA agonist antibody gains US IND clearance
Nov. 5, 2024
Hifibio Therapeutics Inc. has gained IND clearance from the FDA for HFB-200604, a potentially best-in-class BTLA agonist monoclonal antibody for inflammatory and immunology diseases.